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Abstract SPARC is a collagen-binding matricellular pro-
tein. Expression of SPARC in adult tissues is frequently
associated with excessive deposition of collagen and
SPARC-null mice fail to generate a robust fibrotic response
to a variety of stimuli. This review summarizes recent
advancements in the characterization of the binding of
SPARC to collagens and describes the results of studies that
implicate a function for SPARC in the regulation of the
assembly of basal lamina and fibrillar collagen in the ECM.
Potential cellular mechanisms that underlie SPARC activity
in ECM deposition are also explored.
Keywords BM-40.Collagen.Fibrillogenesis.
Osteonectin.Review
Introduction
Secreted Protein Acidic and Rich in Cysteine (SPARC,
osteonectin, BM-40) is a highly conserved matricellular
protein that is expressed in C. elegans, Drosophila,h o n e y
bee, brine shrimp, zebra fish, chicken, and mammals
(Bradshaw and Sage 2001;T a n a k ae ta l .2001; Kucharski
and Maleszka 2002;R o t l l a n te ta l .2008). Worms and
flies, each with one gene encoding SPARC, do not
survive abrogation of SPARC expression (Fitzgerald and
Schwarzbauer 1998;M a r t i n e ke ta l .2008). Ectopic
expression and inhibition of SPARC expression in
amphibians leads to developmental arrest (Purcell et al.
1993;D a m j a n o v s k ie ta l .1997). SPARC-null mice
however, are viable and reproduce perhaps due to
compensation from other SPARC family members such
as hevin/SC1 and SMOC-2 (Sullivan and Sage 2004;L i u
et al. 2008). Although a number of different activities are
associated with SPARC, including processes regulating
proliferation, growth factor activity, matrix metalloprotei-
nase (MMP) activity, and migration—this review will
focus on the interaction of SPARC with collagens and
mechanism(s) by which SPARC might influence the
assembly and deposition of the ECM (Brekken and Sage
2001).
SPARC binding to collagens
SPARC consists of 3 modular domains (Brekken and Sage
2001). The N-terminal region contains a low-affinity, high-
capacity Ca
2+-binding domain. The central portion of the
protein includes a region with homology to follistatin,
whereas the C-terminal, third domain contains two high-
affinity Ca
2+-binding EF hands. The domain of SPARC that
binds collagens and cell surfaces is localized to the third
domain. (Hohenester et al. 1997).
Although SPARC is reported to bind a number of
ECM proteins, SPARC binding to collagens is the best
characterized of these interactions. The binding of
SPARC to collagens is Ca
2+-dependent and requires
non-denatured, triple helical collagen (Sasaki et al.
1998). The affinity of SPARC for collagen IV, the most
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~1-2 μm (Sasaki et al. 1998). SPARC also binds to
fibrillar collagens I, II, III, and V with a similar, or in
some cases, a slightly reduced affinity (Sasaki et al. 1998).
Cleavage of SPARC by MMPs at amino acid L197, or by
an unidentified protease in tissues at residue L198 in helix
αC of the collagen-binding region, results in a ten-fold
increase in the affinity of SPARC for collagens I, II, III, IV
and V (Sasaki et al. 1997). As helix αC partially masks
the collagen-binding site in helix αA, protease cleavage is
predicted to relieve this masking effect thereby increasing
collagen binding. A recombinant form of SPARC
(rSPARC), with aa 196–203 deleted mimics the effects
of protease digestion and generates an “activated” form of
recombinant SPARC (SPARC ΔI, αC; SPARC FS-EC
ΔαC) which engages collagen with a 10-fold higher
affinity than full-length rSPARC (Sasaki et al. 1997).
Tissue-specific differential glycosylation of SPARC also
influences SPARC binding to collagen. For example, the
SPARC that is expressed in bone is modified with high-
mannose structures and exhibits a higher affinity for
collagen I than SPARC from platelets that does not have
the high-mannose modification (Kaufmann et al. 2004).
The SPARC-binding site on collagen I is described in
two separate studies. Wang et al. (2005) identified SPARC
binding sites on collagen I with atomic force microscopy
using rSPARC (generated in insect cells) and rat tail
collagen I or recombinant procollagen I. Similar binding
to procollagen I and collagen extracted from rat tail
(with propeptides removed) was demonstrated. Although
evidence of SPARC binding to collagen I appeared all
along the protein, two preferred sites of interaction with
SPARC, a primary and a secondary site, were reported. The
primary site localized to amino acid residues ~650–800 on
collagen I ~87.5–125 nm from the C-terminus of procolla-
gen I whereas a secondary site mapped nearer the
N-terminus, ~237.5–262.5 nm from the C-terminus,
corresponding to aa 100–200. The primary site at aa 650–
800 overlaps a previously reported α1β1 integrin recogni-
tion site, as well as binding sites for cartilage oligomeric
protein (COMP/thrombospondin 5) and fibronectin, where-
as the secondary site overlaps a potential α2β1 integrin
interaction site (Wang et al. 2005).
In a second study, Giudici et al. (2008), assessed
SPARC collagen interactions by rotary shadowing, fol-
lowed by electron microscopy. Using rSPARC made in
mammalian cells with the helix αC deleted to generate
“activated” SPARC ΔI, αC and human procollagen
produced in vitro by skin fibroblasts, these authors
identified a major SPARC binding site ~180 nm from the
C-terminus of collagen I. Likewise, a nearly identical
region in fibrillar collagens II and III was shown as the
most favored for interaction of SPARC in these studies.
Lesser sites of SPARC binding, in order of preference,
were located at ~80 nm and ~240 nm from the C-terminus.
Guidici et al. (2008) obtained a synthetic triple-helical
peptide representing homotrimeric collagen III aa residues
397–423 in the major binding site (~180 nm from the
C-terminus) and found that SPARC binds this peptide with
an affinity similar to that of full-length procollagen III.
The analogous domain of collagen I is known to contain
binding sites for von Willebrand factor (vWF) and
Discoidin Domain Receptor (DDR) 2.
The primary disagreement between the two SPARC
collagen I binding studies is that Wang et al. did not find
a primary interaction site at the ~180 nm region,
containing the previously characterized vWF/DDR 2
binding domain. Both studies identified the ~80 nm site
and the lesser site ~240 nm from the C-terminus as
SPARC-binding regions. Whether differences in the
source of SPARC (rSPARC from insect cells versus
rSPARC ΔI, αC from mammalian cells) underlie these
results is currently not known. The source of human
procollagen, versus recombinant procollagen, is perhaps
another factor that influences the location of binding sites.
Nonetheless, the identification of SPARC-binding sites on
fibrillar collagens suggests that SPARC can influence the
interaction of collagen with cell-surface collagen receptors
of the integrin and/or DDR family, as well as sites of
collagen interaction with other ECM components includ-
ing fibronectin and/or collagen-binding proteoglycans.
A recent study by Hohenester et al. (2008) reports the
crystal structure of activated rSPARC FS-EC ΔαC bound
to a 33-residue peptide from collagen III representing aa
residues 564–590, the major binding site identified by
Guidici et al. ~180 nm from the C-terminus. SPARC
bound the GVMGFO motif and buried a total of 720 A
2 of
solvent-accessible collagen surface. Engagement of colla-
gen by SPARC is predicted to alter substantially the
conformation of SPARC resulting in a deep pocket that
accommodates the phenylalanine on the trailing collagen
chain (Hohenester et al. 2008). In contrast, the triple helix
of the collagen molecule does not undergo significant
changes upon SPARC binding. Based on data from the
crystal structure, the authors devised a sequence rule that
predicts SPARC interaction sites elsewhere in the collagen
molecule (Hohenester et al. 2008). A second site is
predicted at the GATGFO sequence which is located at
~80 nm from the C-terminus at residue ~700, as shown
previously by atomic force microscopy and by rotary
shadowing (Wang et al. 2005; Giudici et al. 2008). Using
the same sequence rule, Hohenester et al. (2008)p r e d i c t
four SPARC-binding sites in collagen IV, [α1(IV)]2α2
(IV). Of these, one site at position aa 480 in COL4A1 is in
close proximity to a previously identified integrin α1β1
binding site (Kern et al. 1993).
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Fibrillar collagens
The fact that SPARC binds to collagens suggests that
SPARC might influence the assembly of collagen in the
ECM. In fact, the absence of SPARC in mice results in
significant differences in collagen fibril morphology, as
well as substantial decreases in adult tissue concentrations
of collagen. For example, the skin of SPARC-null mice has
~ half the amount of collagen, as measured by hydroxy-
proline analysis, in comparison with wild-type skin
(Bradshaw et al. 2003b). Similar decreases in interstitial
collagen are apparent in heart and in fat depots of SPARC-
null mice (Bradshaw et al. 2003a; Bradshaw et al. 2009).
Collagen fibrils formed in the dermis in the absence of
SPARC are smaller and more uniform in diameter than
those of wild-type animals. Decreases in the average
diameter of collagen fibrils in SPARC-null skin are
significant at 1 month of age and become more substantial
at 6 months of age (Rentz et al. 2007). At 1 month, the
frequency of collagen fibrils with diameters of 60–70 nm is
significantly elevated in the absence of SPARC (Rentz et al.
2007). This size of collagen fibril is proposed to be an
intermediate in collagen fibril assembly that serves as a
substrate for fibril: fibril aggregation to generate larger
collagen fibrils (Ezura et al. 2000). SPARC might serve to
augment collagen fibril fusion directly, and therefore
collagen fibrils accumulate at a size of 60–70 nm in
diameter in its absence.
However, developmental patterns of SPARC expression
together with immunohistochemistry do not support a direct
function of SPARC in mediating fibril fusion. Robust SPARC
expression is evident in post-natal day-1 skin, and drops
significantly by 2 weeks of age with a further decrease at
1 month (Bradshaw et al. 2003b). Collagen fibrils from
2 weeks through 1 month of age continue to undergo active
fibril fusion. In addition, detection of SPARC in association
with extracellular structures, such as collagen fibers, by
immunohistochemistry, is infrequent in skin samples from
animals older than post-natal day 1 (Bradshaw et al. 2003b).
Perhaps, rather than facilitating collagen fibril fusion
directly, the activity of SPARC may be required to generate
collagen fibrils with the capacity to fuse to form larger
fibrils. Guidici et al. (2008) report that rSPARC inhibits
collagen fibrillogenesis assays in vitro. rSPARC was shown
to increase the length of the lag phase of fibrillogenesis,
depending on the molar excess of SPARC over collagen
used in the assay. The lag phase that occurs in vitro during
collagen fibrillogenesis is thought to represent a nucleation
step that is required to initiate collagen fibril formation, and
that is followed by a fiber growth phase. The addition of
equimolar amounts of SPARC ΔI, αC to collagen inhibits
collagen fibrillogenesis completely over the time of the
assay. Addition of either rSPARC or SPARC ΔI, αC
following the lag phase, coincident with the middle of the
growth phase, has no effect on fibrillogenesis in this assay
(Giudici et al. 2008). Hence, the capacity of SPARC to
influence fibrillogenesis is implicated during early steps in
collagen fibril formation.
Basal lamina
Evidence that SPARC also influences basal lamina assembly,
perhaps through an interaction with collagen IV, is supported
by studies both in invertebrates and in vertebrates. SPARC
labeled with green fluorescent protein localizes to basal
lamina structures in C. elegans (Fitzgerald and Schwarzbauer
1998). Abrogation of SPARC expression in flies results in a
lack of collagen IVin the basal lamina of certain structures in
the embryo, notably in the ventral nerve chord, and results in
embryonic lethality (Martinek et al. 2008). SPARC mutant
flies display defects similar to those of collagen IV mutants
suggesting an inter-dependency of these two proteins in
embryonic basal lamina formation in flies (Martinek et al.
2008).
The phenotype of premature cataractogenesis in
SPARC-null mice indicates that SPARC also contributes
to basal lamina assembly in vertebrates (Gilmour et al.
1998). Immunohistochemistry of the basal lamina pro-
duced by lens epithelial cells shows that laminin and
collagen IV are disorganized in the lens capsule of
SPARC-null animals (Yan et al. 2002). Interestingly,
whereas the cell membrane of wild-type epithelial cells
forms a tight, linear surface adjacent to the basal lamina,
SPARC-null epithelial cells appear convoluted, with
abundant membrane protrusions extending into the basal
lamina (Yan et al. 2002). Immunohistochemistry reveals
that these cellular protrusions are β1 integrin-positive.
Perhaps SPARC bound to collagen IV diminishes interac-
tion with cell-surface receptors, such as α1β1,s ot h a t ,i n
SPARC-null mice, increased receptor engagement tethers
collagen IV to cell surfaces interfering with appropriate
basal lamina assembly. The collagen IV network in the lens
basement membrane is less stabilized by non-covalent and
covalent forces in comparison to other basement membranes
and therefore might prove more susceptible to alterations in
structural integrity in the absence of SPARC (Vanacore et al.
2004). Results generated from SPARC-null lens epithelial
cells also reveal an activity of SPARC in the regulation of
laminin deposition as its absence results in an increase
in amounts of laminin in the lens capsule and an
increase in laminin deposited by SPARC-null versus
wild-type lens epithelial cells in vitro (Yan et al. 2005). A
recent report from Greiling et al. (2009) revealed a
disruption in proper circulation of fluids and ions in
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cataract formation in the absence of SPARC is likely
influenced by multiple factors.
Cellular mechanisms of SPARC in ECM assembly
Regulation of collagen binding to cell surface receptors
SPARC purified from media conditioned by parietal yolk
sac (PYS) cells was the first form of SPARC shown to
induce rounding of endothelial cells in culture, and this
together with subsequent studies have led to the character-
ization of SPARC as a counter-adhesive protein (Sage et al.
1989). Exogenous SPARC rounds cells but usually does not
lead to cell lifting and subsequent cell death by anoikis, i.e.
apoptosis induced by cell detachment. Removal of exoge-
nous SPARC reverses rounding and cells reattach without
significant cell death. The counter-adhesive activity of
SPARC is consistent with an activity of SPARC that
interferes with cell-ECM interactions. Along similar lines,
the analysis of collagen interaction with primary dermal
fibroblasts reveal an increase in procollagen, intermediates
of procollagen processing, namely pC collagen I, pN
collagen I, and processed collagen I, in SPARC-null versus
wild-type cells (Rentz et al. 2007). Given the binding sites
of SPARC to collagen, one might predict that SPARC
bound to collagen diminishes cell-surface receptor engage-
ment and thus reduces cell adhesion, whereas collagen
synthesized in the absence of SPARC readily associates
with cell receptors. Alternatively, SPARC has also recently
been shown to affect integrin-linked kinase (ILK) activity
that is predicted to influence integrin ligation independent
of SPARC: collagen interactions (Barker et al. 2005; Nie
and Sage 2009). The role of SPARC in the modulation of
ILK function and downstream pathways is covered in more
detail in the review of SPARC in adipocyte biology by Nie
and Sage in this series.
If SPARC functions to limit collagen engagement
with cell-surface receptors, then could the phenotypic
alterations in ECM assembly, noted in SPARC-null
mice, result from an increased interaction of collagen
with its receptors? The primary SPARC-binding site on
collagen described by Guidici et al. (2008) and further
assessed in Hohenester et al. (2008), is coincident with the
DDR2-binding site on collagen I. DDR2 was shown to
inhibit collagen fibrillogenesis in cultured cells (Mihai et
al. 2006;V o g e le ta l .2006). Hence, if the absence of
SPARC promotes engagement of collagen by DDR2, then
collagen fibril formation might be reduced and/or altered.
Reductions in collagen concentration and compromised
collagen fibril assembly in SPARC-null mice might result
from an increase in DDR2 to collagen interactions.
The ligation of collagen-binding integrin receptors,
namely α1β1, α2β1, and α11β1, may also be diminished
by SPARC binding to collagen (White et al. 2004). In
contrast to DDR2, integrin collagen receptors are thought to
contribute to the formation and/or stability of collagen
fibrils. In vitro, fibronectin assembly precedes and is
required for robust collagen fibril assembly (Velling et al.
2002). Collagen-binding integrin receptors enhance
fibronectin-dependent collagen fibrillogenesis in culture.
For example, in vascular smooth muscle cells, a decrease in
collagen fibrils is observed on cells treated with function-
blocking anti-α2β1 IgG versus control IgG (Li et al. 2003).
Similarly, in mouse embryonic fibroblasts, fibronectin is
required for collagen fibrillogenesis while α11β1, and α2β1
are shown to enhance this process (Velling et al. 2002).
Therefore, an increase in integrin engagement might be
predicted to facilitate collagen fibril assembly and increase
collagen concentrations in tissues, a result not in line with
the ECM phenotype of SPARC-null tissues.
Inaddition to its functional contributions to ECM assembly,
integrin α2β1 is also known to mediate collagen phagocytosis
(Lee et al. 1996). In this case, the lack of SPARC expression
is anticipated to increase collagen turnover at the cell surface
through elevated uptake of collagen by α2β1 engagement. A
plausible scenario might be one in which SPARC, a protein
that supports collagen deposition, interferes with receptor
interactions on collagen that inhibit fibril formation and/or
promote collagen turnover (Fig. 1).
Regulation of processing of procollagen propeptides
Whether SPARC acts exclusively in the extracellular space
to modulate collagen interactions with cell-surface recep-
tors or acts intracellularly in collagen trafficking and post-
translation modification remains to be elucidated. SPARC
might influence collagen I production and deposition at a
number of different steps. A series of post-translational
modifications of collagen I occur in the endoplasmic
reticulum, the cis-Golgi, and possibly in trans-Golgi
compartments, that produce hydroxylated amino acids,
sugar modifications with carbohydrates, trimeric chain
assembly, and finally secretion of correctly assembled
procollagen I (Prockop and Kivirikko 1995). SPARC is
also present in the secretory pathway raising the possibility
that intracellular interaction of SPARC with collagen I
might influence collagen I modifications and assembly. The
hypothesis that SPARC serves as an intracellular collagen
chaperone that is important in the latter stages of collagen
secretion was put forth by Martinek et al. (2007) based
primarily on results from experiments with Drosophila and
collagen IV. Along these lines, chaperone folding activity is
exhibited by SPARC in assays performed in vitro (Emerson
et al. 2006).
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accumulation of procollagen I is not evident in SPARC-null
fibroblasts as would be predicted in the event that SPARC
were critical for post-translational modification and/or
sorting of procollagens (Rentz et al. 2007). Once secreted,
procollagenI is convertedtomaturecollagenIbyN-propeptide
proteinases, specifically ADAMTS-2 (A Disintegrin And
Metalloproteinase with ThromboSpondin motifs), that excises
the N-terminal propeptide to generate pC collagen I, and by
the C-propeptide proteinase, Bone Morphogenic Protein
(BMP)-1, that excises the C-propeptide to produce pN
collagen I (Porter et al. 2005; Hopkins et al. 2007). The
collagen on primary murine dermal fibroblast cell
surfaces is therefore comprised of four different forms:
procollagen I, pC collagen I, pN collagen I, and
collagen I. In the absence of SPARC, in addition to
an increase in total amounts of cell-associated collagen
I, processed collagen I (with both propeptides removed)
represents a greater proportion of total collagen than in
wild-type cells (Rentz et al. 2007). Hence, SPARC
appears to serve a function in the regulation of procolla-
gen processing that is generally considered to occur in the
extracellular space. Although in embryonic tendon, some
intracellular processing of propeptides is observed indi-
cating that, at least in some cell types, procollagen
processing can occur in secretory vesicles prior to
secretion (Canty and Kadler 2005). The mechanism by
which SPARC modulates procollagen processing, whether
intra or extracellular, is actively under investigation.
In some cases, propeptides are retained following
incorporation into fibrils (Fleischmajer et al. 1988). During
development in the skin of chicks, antibodies against the N-
propeptide of collagen I were immuno-localized exclusive-
ly to the surface of collagen fibrils 20–40 nm in diameter
(Fleischmajer et al. 1983). Hence, processing of the
propeptides of collagen I represents a possible mechanism
in the regulation collagen fibrillogenesis (Holmes et al.
1996). Retention of the propeptides of collagen I (and
proteins bound to propeptides) following incorporation into
fibrils, for example, could present a steric hindrance to fibril
aggregation and thus limit fibril expansion.
Alternatively,someevidencesuggeststhattheN-propeptide
acts to enhance collagen I fibril aggregation (Watson et al.
1998). In this case, premature processing of the N-propeptide
might limit fibril expansion. In vitro, the absence of SPARC
is associated with greater procollagen processing, as judged
by propeptide cleavage. In the event that the absence of
SPARC in vivo results in a similar increase, perhaps the
premature removal of the N-propeptide generates collagen
fibrils without N-propeptides that are less efficient in fibril
fusion. Given the result that SPARC inhibits collagen
fibrillogenesis in vitro, specifically during the lag phase of
initiation, one possibility is that SPARC binds nascent
monomeric collagen I (and/or procollagen I) and delays its
incorporation into nascent fibrils until events such as
propeptide processing and/or engagement of proteoglycans
(including fibromodulin, lumican, decorin, etc.) occur in a
precise spatial and temporal sequence in the pericellular
space. In the absence of SPARC expression then, the precise
regulation of procollagen maturation to collagen is altered
and the efficiency of collagen deposition to the insoluble
ECM is compromised.
SPARC as an anti-fibrotic target or promoter of ECM
assembly
SPARC expression is consistently found coincident with
expression of fibrillar collagens and is therefore frequently
elevated in adult tissues undergoing wound repair or in
tissues with fibrotic disease. Mouse models characterized
by renal, cardiac, lung, and dermal fibrosis performed in
SPARC-null mice demonstrate reduced collagen deposition
versus that in wild-type mice (Strandjord et al. 1999;
Fig. 1 SPARC activity in modulating collagen cell interaction and
procollagen processing. In a, procollagen fibrils are bound by SPARC,
which diminishes collagen engagement by cell-surface receptors. In
the absence of SPARC b, procollagen interacts with receptors to a
greater degree and is tethered to cell surfaces. Propeptide cleavage is
enhanced in the pericellular milieu. SPARC-null fibrils fail to
aggregate as efficiently as fibrils on wt cells. One SPARC molecule
is shown here binding to one collagen molecule for simplicity. Three
sites are known to preferentially bind SPARC on the collagen
molecule albeit with varying degrees of efficiency. From (Rentz et
al. 2007) with permission
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2009). Given the significant effects of the loss of SPARC
expression on collagen levels in SPARC-null mice, SPARC
represents an attractive target for reducing collagen deposition
in fibrosis. Scleroderma is a disease characterized by fibrotic
deposition of collagen. Targeting SPARC expression by
siRNA in fibroblasts from individuals with scleroderma
reduces collagen I expression in vitro (Zhou et al. 2006).
Furthermore, in a rat model of liver fibrosis, Camino et al.
(2008) demonstrated that anti-sense RNA against SPARC,
delivered by adenovirus, reduces collagen deposition as
measured by histological and by hydroxyproline analysis.
These studies suggest that inhibition of SPARC is sufficient
to decrease collagen accumulation in tissues and further
validate the development of tools that target SPARC activity
to alleviate fibrosis in a variety of tissues.
As a reduction in SPARC expression diminishes collagen
accumulationintheECM,anincreaseinSPARCexpressionis
anticipated to enhance collagen deposition. In heart, myocar-
dial infarction (MI) is associated with rapid synthesis of a
collagenousscartoreducetheriskofcardiacrupture.SPARC-
null mice are compromised in myocardial collagen formation
and exhibit a greater mortality due to cardiac rupture
following MI in comparison with wild-type mice (Bradshaw
et al. 2009; Schellings et al. 2009). The production of
SPARC, delivered by adenoviral expression in SPARC-null
animals, improved collagen fiber assembly and reduced the
mortality of SPARC-null animals with infarctions to that of
wild-type mice (Schellings et al. 2009). Importantly, over-
expression of SPARC by adenoviral delivery in wild-type
animals subjected to infarction further enhanced collagen
assembly in these mice and improved cardiac function
(Schellings et al. 2009). Similar results from experiments
using injected glioma cells demonstrated increased collage-
nous ECM production in vivo, that was associated with cells
that over-expressed SPARC, in comparison with the use of
control cells (Yunker et al. 2008). Taken together, these
studies provide evidence that increased expression of
SPARC stimulates increased collagen deposition and assem-
bly into the ECM.
The evidence that SPARC influences TGF-β activity has
been reported in several different cell types. In epithelial
cells and in mesangial cells, SPARC was shown to enhance
TGF-β1 activity through an as yet undefined mechanism
(Schiemann et al. 2003; Francki et al. 2004). In addition,
resident cells of the infarct scar in wild-type mouse hearts
with over-expression of SPARC demonstrated increased
levels of activated Smad2, a down-stream element in the
TGF-β1 signaling cascade (Schellings et al. 2009). Hence,
there is concern that long term exposure to elevated levels
of SPARC in a therapeutic setting might give rise to
unexpected deleterious outcomes associated with increased
TGF-β activity. Further characterization of the mechanism
(s) by which SPARC modulates TGF-β1 signaling will
provide insight in this regard.
Conclusions
In this review, a summary of results that support a
function for SPARC as a critical factor in the formation
of a collagenous ECM has been presented. In particular,
SPARC is shown to play a prominent role in the
deposition of fibrotic collagen in adult tissues. As such,
analyses to elucidate the functional basis of SPARC
activity in the regulation of collagen assembly have the
potential to provide new insight into synthesis of the
ECM and to suggest ways to control the formation of a
pathological ECM. Conversely, in instances in which
collagen deposition is required, for example in the
synthesis of bioengineered tissues, an increased expres-
sion of SPARC can be expected to facilitate and
enhance ECM assembly.
SPARC can influence the interaction of collagen with the
cell surface possibly through modulation of receptor
binding. In addition, purified SPARC inhibits collagen
fibrillogenesis in a cell autonomous manner during early
stages of fibril initiation in vitro. Thus SPARC has at least
two roles in collagen fibril assembly–one that modulates
interaction of collagen with the cell surface and another that
regulates collagen incorporation to fibrils. Whether similar
mechanisms involving the interaction of SPARC with
collagen IV regulate basal lamina assembly is currently
not known. Much remains to be learned from future studies
that will hopefully discover the precise mechanisms that
govern SPARC activity in ECM formation. These studies
will no doubt bring novel and exciting ideas to the field of
collagen and matricellular biology.
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